Danger from the Wild: HIV, Can We Conquer It?

Home | About | Credits | Seminar List | Poster | Feedback

Danger from the Wild: HIV, Can We Conquer It?
David Baltimore, Feb. 2007
California Institute of Technology

Lecture Overview
In this last segment, I describe another gene therapy strategy for HIV in which we propose to develop antibody-like proteins that can be expressed by a patient's B cells and will target the HIV virus for destruction. To achieve this objective, hematopoietic (blood) stem cells must to be targeted with the gene, which will ultimately develop into B cells that express the therapeutic molecule. The ultimate goal is to produce a life-long supply of anti-HIV neutralizing antibodies. In this lecture, I describe the molecular methods underlying this strategy and a development path from proof-of-principle studies in mouse to safe trials in humans. This project receives funding from the Bill and Melinda Gates Foundation.
Part 3: The Grand Challenge: Engineering Immunity (18:51)

Click image above to start seminar in 320x240 format
Click here to view in larger 640x480 format*
QuickTime 7 Required    *640x480 System Requirements
(there may be a few seconds delay before seminars start)

Downloads in alternative formats:
(To Save, Right Click a link below and select "Save Target/Link As")
QuickTime (34mb)     MP4 (220mb)     iPod/iPhone Video (220mb)
PowerPoint Slides 1/page (838mb)     PowerPoint Slides 6/page (456kb)

MP4 (221mb)

Format Descriptions
Download Accelerator/Resume Broken Downloads Software

Part 1: Introduction to Viruses: HIV and Non-equilibrium Viruses (34:06)

Part 2: Why Gene Therapy Might be a Reasonable Tool for Attacking HIV (30:08)

Speaker Bio    Related Articles

Disclaimers, Trademarks, & Terms of Use
© 2008 The American Society for Cell Biology
8120 Woodmont Avenue Suite 750, Bethesda, MD 20814-2762
Phone: (301) 347-9300 Fax: (301) 347-9310

Lecture Overview In this last segment, I describe another gene therapy strategy for HIV in which we propose to develop antibody-like proteins that can be expressed by a patient's B cells and will target the HIV virus for destruction. To achieve this objective, hematopoietic (blood) stem cells must to be targeted with the gene, which will ultimately develop into B cells that express the therapeutic molecule. The ultimate goal is to produce a life-long supply of anti-HIV neutralizing antibodies. In this lecture, I describe the molecular methods underlying this strategy and a development path from proof-of-principle studies in mouse to safe trials in humans. This project receives funding from the Bill and Melinda Gates Foundation.	Part 3: The Grand Challenge: Engineering Immunity (18:51) Click image above to start seminar in 320x240 format Click here to view in larger 640x480 format* QuickTime 7 Required 640x480 System Requirements (there may be a few seconds delay before seminars start) Downloads in alternative formats:* (To Save, Right Click a link below and select "Save Target/Link As") QuickTime (34mb) MP4 (220mb) iPod/iPhone Video (220mb) PowerPoint Slides 1/page (838mb) PowerPoint Slides 6/page (456kb) MP4 (221mb) Format Descriptions Download Accelerator/Resume Broken Downloads Software
Part 1: Introduction to Viruses: HIV and Non-equilibrium Viruses (34:06) Part 2: Why Gene Therapy Might be a Reasonable Tool for Attacking HIV (30:08) Speaker Bio Related Articles